The case of Africa's 'vanishing' carbon deals
The case of Africa's 'vanishing' carbon deals

By AFP's Evelyn Kpadeh Seagbeh and Code for Africa's Kunle Adebajo
Washington (AFP) | 16/07/2026 - 20:35:13 | US forces launch new strikes against Iran: US military
Brasília (AFP) | 16/07/2026 - 20:05:48 | Brazil FM slams Rubio for 'crude and arrogant' remarks about Lula
Washington (AFP) | 16/07/2026 - 19:42:37 | Trump teleprompter operator suspended over betting allegations: White House
Washington (AFP) | 16/07/2026 - 19:29:00 | Trump to address nation on 'integrity of our elections': White House
Washington (AFP) | 16/07/2026 - 19:07:48 | US designates Mexico's Juarez and Los Viagras cartels as terror groups
Paris (AFP) | 16/07/2026 - 18:56:05 | At least 12,000 excess deaths from Europe's June heatwave: AFP analysis
Kyiv (AFP) | 16/07/2026 - 18:25:44 | Zelensky appoints intelligence official as acting defence minister
Tehran (AFP) | 16/07/2026 - 17:29:27 | US strikes hit around Iran's Qeshm island: Iranian media
Sanaa (AFP) | 16/07/2026 - 17:01:01 | Yemen's Houthis threaten attacks on Saudi oil facilities
Kyiv (AFP) | 16/07/2026 - 16:53:58 | Ukraine denies killing chief engineer of Russian-occupied nuclear plant

By AFP's Evelyn Kpadeh Seagbeh and Code for Africa's Kunle Adebajo
ChatEurope, the go-to platform for European affairs created by leading European media outlets, enhances its offer with the launch of key EU events live video coverage.
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on...
Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo a...
The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not mee...
COOCON (CEO Kim Jong-hyun, KOSDAQ: 294570), a business data platform company in South Korea, announced on June 29 that it is accelerating its push into the Model Context Protocol (MCP)-based data business for the AI agent era. Under the plan, COOCON aims to grow into a “dedicated data hub for AI agents” by delivering its existing data in MCP format so AI agents can utilize it directly. With over 20 years of expertise in collecting and connecting data across finance, the public sector, logisti...
Seiden Law LLP (“Seiden Law”), legal counsel for Mr. Leak Yim, a Cambodia national, and his family, announces the filing of an application in U.S. federal district court in Washington D.C., seeking court-ordered discovery to uncover the false and misleading information that may have led to mistaken prosecution in Thailand of Mr. Yim as well as his unwarranted identification to Congress as being associated with scam centers in Asia. 28 U.S.C. § 1782 (“1782”) provides powerful evidence-gatherin...
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Divi...
Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associ...